Loading cancer entity…
Loading cancer entity…
Clinical trials
3,384 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (537)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT01432353 | A Study of DFRF4539A in Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 39 | Genentech, Inc.INDUSTRY | 1 | Nov 2, 2016 | clinicaltrials |
| NCT01580371 | Safety and Pharmacokinetic Profile of CKD-581(CKD-581) | completed | Phase 1 | 39 | Chong Kun Dang PharmaceuticalINDUSTRY | 1 | Oct 6, 2016 | clinicaltrials |
| NCT01457417 |
| A Study of DKN-01 in Multiple Myeloma or Advanced Solid Tumors |
| completed |
| Phase 1 |
| 32 |
| Leap Therapeutics, Inc.INDUSTRY |
| 1 |
| Sep 28, 2016 |
| clinicaltrials |
| NCT01718899 | Phase 1/2a Study of Cancer Vaccine to Treat Smoldering Multiple Myeloma | completed | Phase 1 | 22 | OncoPep, Inc.INDUSTRY | 1 | Sep 28, 2016 | clinicaltrials |
| NCT02116569 | A Study of Daratumumab in Japanese Participants With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 9 | Janssen Pharmaceutical K.K.INDUSTRY | 1 | Sep 26, 2016 | clinicaltrials |
| NCT00891592 | Umbilical Cord Blood Transplant for Hematological Malignancies(UCB) | completed | Phase 1 | 5 | University of PennsylvaniaOTHER | 1 | Aug 19, 2016 | clinicaltrials |
| NCT00560391 | Dasatinib in Combination With Revlimid (and Dexamethasone) | completed | Phase 1 | 35 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 4, 2016 | clinicaltrials |
| NCT01114282 | Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM | completed | Phase 1 | 11 | Stanford UniversityOTHER | 1 | Jul 6, 2016 | clinicaltrials |
| NCT00990717 | Safety Study Looking at the Use of a Natural Killer Cell Line Against Hematological Malignancies | completed | Phase 1 | 8 | University Health Network, TorontoOTHER | 1 | Jun 23, 2016 | clinicaltrials |
| NCT00698776 | Combination of Lenalidomide and Autologous Mature Dendritic Cells Pulsed With KRN7000 in Myeloma | completed | Phase 1 | 6 | Yale UniversityOTHER | 1 | Jun 21, 2016 | clinicaltrials |
| NCT01079936 | Lenalidomide and High-Dose Melphalan | completed | Phase 1 / Phase 2 | 61 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 6, 2016 | clinicaltrials |
| NCT00410982 | Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies | completed | Phase 1 | 145 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 3, 2016 | clinicaltrials |
| NCT01034553 | Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 26 | Mayo ClinicOTHER | 1 | May 25, 2016 | clinicaltrials |
| NCT00299767 | Phase I Study of Sequential Cord Blood Transplants | completed | Phase 1 | 21 | Massachusetts General HospitalOTHER | 1 | May 11, 2016 | clinicaltrials |
| NCT00406978 | Melphalan, Prednisone, Thalidomide and Defibrotide in Relapsed Multiple Myeloma Patients(MPTD) | completed | Phase 1 / Phase 2 | 24 | Silvio AimeOTHER | 1 | May 10, 2016 | clinicaltrials |
| NCT01204164 | Phase 1 Study of TG02 Citrate in Patients With Advanced Hematological Malignancies(TG02-101) | completed | Phase 1 | 120 | Tragara Pharmaceuticals, Inc.INDUSTRY | 1 | May 6, 2016 | clinicaltrials |
| NCT00833833 | MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma | completed | Phase 1 / Phase 2 | 259 | Celgene CorporationINDUSTRY | 2 | Apr 27, 2016 | clinicaltrials |
| NCT01394354 | Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)(VBDD) | completed | Phase 1 / Phase 2 | 34 | University Hospital FreiburgOTHER | 1 | Apr 6, 2016 | clinicaltrials |
| NCT00552396 | An Open-label, Dose-escalation Safety and Tolerability Trial Assessing Anti-KIR (1-7F9) in Subjects With Multiple Myeloma | completed | Phase 1 | 32 | Innate PharmaINDUSTRY | 1 | Mar 31, 2016 | clinicaltrials |
| NCT01359657 | Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 46 | Bristol-Myers SquibbINDUSTRY | 1 | Mar 16, 2016 | clinicaltrials |
| NCT01352338 | Revlimid, Endoxan, Prednison Evaluation After Prior Revlimid Treatment (REPEAT)(REPEAT) | completed | Phase 1 / Phase 2 | 82 | UMC UtrechtOTHER | 1 | Feb 26, 2016 | clinicaltrials |
| NCT01413568 | Safety and Efficacy of POL6326 for Mobilization/Transplant of Sibling Donor in Patients With Hematologic Malignancies | completed | Phase 1 / Phase 2 | 38 | Polyphor Ltd.INDUSTRY | 1 | Feb 26, 2016 | clinicaltrials |
| NCT00153933 | Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma | completed | Phase 1 | 58 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 25, 2016 | clinicaltrials |
| NCT00594126 | Safety and Dose Study of GRN163L Administered to Treat Patients With Refractory or Relapsed Multiple Myeloma | completed | Phase 1 | 20 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00718601 | Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma | completed | Phase 1 | 40 | Geron CorporationINDUSTRY | 1 | Dec 24, 2015 | clinicaltrials |
| NCT00693433 | Temsirolimus and Dexamethasone in Treating Patients With Recurrent or Refractory Multiple Myeloma | completed | Phase 1 | 15 | National Cancer Institute (NCI)NIH | 1 | Dec 4, 2015 | clinicaltrials |
| NCT00276536 | Interferon Alfa in Treating Patients With Stage IV Solid Tumors, Lymphoma, or Myeloma(IFNa) | completed | Phase 1 | 35 | The Cleveland ClinicOTHER | 1 | Oct 14, 2015 | clinicaltrials |
| NCT01485835 | A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma | completed | Phase 1 | 8 | Emory UniversityOTHER | 1 | Oct 12, 2015 | clinicaltrials |
| NCT00915408 | A Dose Escalation Study of the Combination of Lenalidomide (Revlimid®), Dexamethasone and Cyclophosphamide in Patients Refractory or Relapsing From Stable Disease With Multiple Myeloma(CRD) | completed | Phase 1 / Phase 2 | 32 | King's College Hospital NHS TrustOTHER | 1 | Sep 2, 2015 | clinicaltrials |
| NCT00060632 | Safety Study of Ridaforolimus in Patients With Advanced, Refractory or Recurrent Malignancies (MK-8669-001 AM5)(COMPLETED) | completed | Phase 1 | 46 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Aug 27, 2015 | clinicaltrials |
| NCT00060645 | Safety Study of AP23573 in Patients With Advanced, Refractory or Recurrent Malignancies (8669-013)(COMPLETED) | completed | Phase 1 | 33 | Merck Sharp & Dohme LLCINDUSTRY | 1 | Aug 27, 2015 | clinicaltrials |
| NCT01658319 | Methoxyamine and Fludarabine Phosphate in Treating Patients With Relapsed or Refractory Hematologic Malignancies | completed | Phase 1 | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 13, 2015 | clinicaltrials |
| NCT00689507 | A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib | completed | Phase 1 | 48 | Applied Molecular EvolutionINDUSTRY | 1 | Jun 29, 2015 | clinicaltrials |
| NCT01531998 | Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM) | completed | Phase 1 / Phase 2 | 14 | M.D. Anderson Cancer CenterOTHER | 1 | Jun 19, 2015 | clinicaltrials |
| NCT01344876 | Phase I Study of OPB-51602 in Patients With Hematologic Malignancies | completed | Phase 1 | 20 | Otsuka Pharmaceutical Co., Ltd.INDUSTRY | 1 | Jun 8, 2015 | clinicaltrials |
| NCT00111813 | Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1)) | completed | Phase 1 | 34 | Merck Sharp & Dohme LLCINDUSTRY | 0 | May 21, 2015 | clinicaltrials |
| NCT00778752 | Dose-finding of Lenalidomide as Maintenance in Multiple Myeloma | completed | Phase 1 / Phase 2 | 24 | Universitätsklinikum Hamburg-EppendorfOTHER | 1 | May 13, 2015 | clinicaltrials |
| NCT00871663 | Phase 1 Weekly Dosing of SCH 727965 in Patients With Advanced Cancer (Study P04629AM6) | completed | Phase 1 | 123 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Apr 20, 2015 | clinicaltrials |
| NCT01533194 | Viral Therapy in Treating Patients With Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | National Cancer Institute (NCI)NIH | 1 | Apr 15, 2015 | clinicaltrials |
| NCT00972712 | Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma | completed | Phase 1 | 12 | Emory UniversityOTHER | 2 | Mar 10, 2015 | clinicaltrials |
| NCT00809276 | Allo BMT Using Matched Related/Unrelated Donors With FluBu and HiCY | completed | Phase 1 / Phase 2 | 92 | Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER | 1 | Feb 16, 2015 | clinicaltrials |
| NCT00343798 | A Pilot Study to Evaluate the Co-Infusion of Ex Vivo Expanded Cord Blood Cells With an Unmanipulated Cord Blood Unit in Patients Undergoing Cord Blood Transplant for Hematologic Malignancies | completed | Phase 1 | 23 | Fred Hutchinson Cancer CenterOTHER | 1 | Feb 11, 2015 | clinicaltrials |
| NCT01219010 | A Study Evaluating the Effects of Siltuximab on the Heart in Patients With Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Indolent Multiple Myeloma | completed | Phase 1 | 30 | Janssen Research & Development, LLCINDUSTRY | 3 | Jan 19, 2015 | clinicaltrials |
| NCT00082784 | Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms | completed | Phase 1 | 93 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT01330173 | Vismodegib After Stem Cell Transplant in Treating Patients With High-Risk First Remission or Relapsed Multiple Myeloma | completed | Phase 1 | 50 | National Cancer Institute (NCI)NIH | 1 | Dec 23, 2014 | clinicaltrials |
| NCT00079716 | Study of SGN-40 in Patients With Refractory or Recurrent Multiple Myeloma | completed | Phase 1 | 44 | Seagen Inc.INDUSTRY | 1 | Dec 18, 2014 | clinicaltrials |
| NCT00991562 | IMGN901 in Combination With Lenalidomide and Dexamethasone | completed | Phase 1 | 50 | ImmunoGen, Inc.INDUSTRY | 1 | Nov 21, 2014 | clinicaltrials |
| NCT00891137 | Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | completed | Phase 1 | 30 | Cellerant TherapeuticsINDUSTRY | 1 | Oct 27, 2014 | clinicaltrials |
| NCT00070616 | Pharmacokinetic Study of Palifermin in Subjects Receiving Radiation Therapy and Chemotherapy Followed by Blood Stem Cell Support | completed | Phase 1 | 25 | Swedish Orphan BiovitrumINDUSTRY | 0 | Oct 24, 2014 | clinicaltrials |
| NCT00525447 | Study of SGN-40, Lenalidomide, and Dexamethasone in Patients With Multiple Myeloma | completed | Phase 1 | 36 | Seagen Inc.INDUSTRY | 1 | Oct 9, 2014 | clinicaltrials |
Data updated 23 days agoSource updated Nov 2, 2016source: clinicaltrials